Nordicus Partners Corp and Industry Updates
Nordique Engages Machai Capital Corp for Digital Marketing Services
On June 18, 2025, Nordique Resources Inc., a company listed on the OTC Bulletin Board, announced its engagement with Machai Capital Corp. to enhance its corporate awareness and digital marketing efforts. The agreement, set for an initial term of three months, is renewable for an additional three months. Machai Capital will leverage its expertise in branding, content and data optimization, search engine optimization, search engine marketing, lead generation, and social media to support Nordique’s strategic objectives.
Financial Overview of Nordicus Partners Corp
Nordicus Partners Corp, a health care equipment and supplies company based in Wilmington, United States, operates within the Health Care Equipment & Supplies sector. As of June 17, 2025, the company’s close price was $4, with a 52-week high of $10.16 on December 29, 2024, and a 52-week low of $2.76 on December 8, 2024. The market capitalization stands at $64,610,000 USD. The company’s price-to-earnings ratio is currently at -9.57, reflecting its financial performance and market valuation.
DMEGC Solar’s Success at SNEC 2025
In a separate industry update, DMEGC Solar has emerged as a leader in the solar industry following its participation in SNEC 2025, one of the world’s leading solar energy exhibitions. The company showcased its latest high-efficiency photovoltaic (PV) modules and received multiple prestigious awards for its innovation, reliability, and sustainability. Among the highlights was the Infinity RT Series G12RT-B66DSW module, which is expected to achieve a maximum mass production power of 660W and a 24.4% conversion efficiency.
Foresee Pharmaceuticals’ Phase 3 Casppian Trial Milestone
Foresee Pharmaceuticals announced a significant milestone in its Phase 3 Casppian trial for Central Precocious Puberty (CPP). The multicenter, multinational study, evaluating the efficacy and safety of leuprolide mesylate (FP-001) 42 mg controlled-release, has reached complete enrollment. Topline results are anticipated by the end of 2025, with plans to submit a New Drug Application (NDA) to regulatory authorities by Q3 2026, contingent on successful trial outcomes.
These updates reflect significant developments in the health care and renewable energy sectors, highlighting strategic partnerships, financial performance, and innovative advancements.